Risk for Hospitalization for Heart Failure Down With SGLT-2i Treatment for T2D
TUESDAY, May 24, 2022 -- For patients with type 2 diabetes (T2D) receiving first-line sodium-glucose cotransporter-2 inhibitors (SGLT-2i), the risk for stroke, myocardial infarction (MI), and all-cause mortality is similar to those receiving...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | Heart Failure | Pharmaceuticals | Sodium | Stroke